Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $57 | $121 | $157 | $351 |
| - Cash | $151 | $77 | $78 | $60 |
| + Debt | $10 | $11 | $12 | $13 |
| Enterprise Value | -$83 | $55 | $91 | $303 |
| Revenue | $82 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $82 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | $51 | -$31 | -$33 | -$37 |
| % Margin | 61.9% | – | – | – |
| Net Income | $51 | -$31 | -$34 | -$37 |
| % Margin | 62.1% | – | – | – |
| EPS Diluted | 0.99 | -0.6 | -0.65 | -0.72 |
| % Growth | 265% | 7.7% | 9.7% | – |
| Operating Cash Flow | $59 | -$32 | -$23 | -$33 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $59 | -$32 | -$24 | -$33 |